Joleen Hubbard, MD
Medical Oncology · Rochester, MNNPI 1952351009
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,226 of the $59,172 with a category attached, or 74.7%. 14 manufacturers reported payments, led by Bayer at 31.4% of the total. 2025 is the largest year on record at $18,382, 7.8 times the $2,342 reported in 2019.
Across 58 payments — averaging $1020.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$19K
- Incyte Corporation$16K
- Taiho Oncology, Inc.$5K
- Merck$4K
- Amgen$3K
- Seagen Inc.$3K
- plus $10K from 8 others
Across 350 payments — averaging $5067.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$682K
- Amgen$240K
- Seagen Inc.$218K
- G1 Therapeutics, Inc.$167K
- Incyte Corporation$154K
- Taiho Oncology, Inc.$112K
- plus $201K from 5 others
What the payments were for
- Consulting fees$44,22675%
- Speaking & faculty fees$12,33021%
- Travel & lodging$1,1752%
- Food & beverage$1,4272%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 18 | $18,576 |
| Incyte Corporation | 16 | $15,905 |
| Taiho Oncology, Inc. | 5 | $5,086 |
| Merck | 3 | $4,261 |
| Amgen | 1 | $2,744 |
| Seagen Inc. | 3 | $2,679 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| AstraZeneca | 1 | $2,050 |
| Eisai Inc. | 1 | $1,900 |
| G1 Therapeutics, Inc. | 2 | $1,697 |
| Daiichi Sankyo Inc. | 1 | $1,451 |
| Histosonics, Inc. | 1 | $233 |
| Array Biopharma Inc | 3 | $153 |
| Pfizer | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,172 in reported general payments places this provider in the 85th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 58 | $520 |
| Dexamethasone | 42 | $504 |
| Ondansetron Hcl | 52 | $318 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $146 |
| LoperamideLoperamide Hcl | 14 | $119 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Lionel Aurelien Kankeu FonkouaRochester$58K
- Kaushal ParikhRochester$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.